Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs

Astrid A M Van der Veldt; Mark Lubberink; Idris Bahce; Maudy Walraven; Michiel P de Boer; Henri N J M Greuter; N Harry Hendrikse; Jonas Eriksson; Albert D Windhorst; Pieter E Postmus; Henk M Verheul; Erik H Serné; Adriaan A Lammertsma; Egbert F Smit

doi:10.1016/j.ccr.2011.11.023

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs

Astrid A M Van der Veldt, Mark Lubberink, Idris Bahce, Maudy Walraven, Michiel P de Boer, Henri N J M Greuter, N Harry Hendrikse, Jonas Eriksson, Albert D Windhorst, Pieter E Postmus, Henk M Verheul, Erik H Serné, Adriaan A Lammertsma, Egbert F Smit

Research output: Contribution to journal › Article › Academic › peer-review

295 Citations (Scopus)

Abstract

Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([(11)C]docetaxel). In NSCLC, bevacizumab reduced both perfusion and net influx rate of [(11)C]docetaxel within 5 hr. These effects persisted after 4 days. The clinical relevance of these findings is notable, as there was no evidence for a substantial improvement in drug delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.

Original language	English
Pages (from-to)	82-91
Number of pages	10
Journal	Cancer Cell
Volume	21
Issue number	1
DOIs	https://doi.org/10.1016/j.ccr.2011.11.023
Publication status	Published - 17 Jan 2012
Externally published	Yes

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ccr.2011.11.023

Cite this

Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., Verheul, H. M., Serné, E. H., Lammertsma, A. A., & Smit, E. F. (2012). Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell, 21(1), 82-91. https://doi.org/10.1016/j.ccr.2011.11.023

@article{cfedeb23591a4b48b064f4dfed506153,

title = "Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs",

abstract = "Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([(11)C]docetaxel). In NSCLC, bevacizumab reduced both perfusion and net influx rate of [(11)C]docetaxel within 5 hr. These effects persisted after 4 days. The clinical relevance of these findings is notable, as there was no evidence for a substantial improvement in drug delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.",

author = "{Van der Veldt}, {Astrid A M} and Mark Lubberink and Idris Bahce and Maudy Walraven and {de Boer}, {Michiel P} and Greuter, {Henri N J M} and Hendrikse, {N Harry} and Jonas Eriksson and Windhorst, {Albert D} and Postmus, {Pieter E} and Verheul, {Henk M} and Sern{\'e}, {Erik H} and Lammertsma, {Adriaan A} and Smit, {Egbert F}",

year = "2012",

month = jan,

day = "17",

doi = "10.1016/j.ccr.2011.11.023",

language = "English",

volume = "21",

pages = "82--91",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "1",

}

Van der Veldt, AAM, Lubberink, M, Bahce, I, Walraven, M, de Boer, MP, Greuter, HNJM, Hendrikse, NH, Eriksson, J, Windhorst, AD, Postmus, PE, Verheul, HM, Serné, EH, Lammertsma, AA & Smit, EF 2012, 'Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs', Cancer Cell, vol. 21, no. 1, pp. 82-91. https://doi.org/10.1016/j.ccr.2011.11.023

TY - JOUR

T1 - Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy

T2 - implications for scheduling of anti-angiogenic drugs

AU - Van der Veldt, Astrid A M

AU - Lubberink, Mark

AU - Bahce, Idris

AU - Walraven, Maudy

AU - de Boer, Michiel P

AU - Greuter, Henri N J M

AU - Hendrikse, N Harry

AU - Eriksson, Jonas

AU - Windhorst, Albert D

AU - Postmus, Pieter E

AU - Verheul, Henk M

AU - Serné, Erik H

AU - Lammertsma, Adriaan A

AU - Smit, Egbert F

PY - 2012/1/17

Y1 - 2012/1/17

N2 - Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([(11)C]docetaxel). In NSCLC, bevacizumab reduced both perfusion and net influx rate of [(11)C]docetaxel within 5 hr. These effects persisted after 4 days. The clinical relevance of these findings is notable, as there was no evidence for a substantial improvement in drug delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.

AB - Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([(11)C]docetaxel). In NSCLC, bevacizumab reduced both perfusion and net influx rate of [(11)C]docetaxel within 5 hr. These effects persisted after 4 days. The clinical relevance of these findings is notable, as there was no evidence for a substantial improvement in drug delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.

U2 - 10.1016/j.ccr.2011.11.023

DO - 10.1016/j.ccr.2011.11.023

M3 - Article

C2 - 22264790

SN - 1535-6108

VL - 21

SP - 82

EP - 91

JO - Cancer Cell

JF - Cancer Cell

IS - 1

ER -

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this